Market news

Motley Fool Press Release.

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

Enovis is back in focus for investors after a modest reset in its implied price target, with fair value in one model shifting from US$42.30 to about US$38.33. Analysts link this move to fresh thinking on the eCential Robotics acquisition, recent free cash flow trends, and the latest Q2 read through to growth plans and execution risk. As you read on, you will see how these moving parts shape the evolving Enovis story and what to watch next in the analyst narrative. Stay updated as the Fair...

Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.

2026-09-02. The following slide deck was published by Enovis Corporation in conjunction with this event.

The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.

Enovis (NYSE:ENOV) said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery. Chief Executive Officer Damien Mc

Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 mi

Enovis (ENOV) has an average rating of buy and mean price target of $41.58, according to analysts po

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

Enovis (ENOV) shares were down 10% in Thursday trading after the company reported its results for fi

Enovis (ENOV) delivered earnings and revenue surprises of +8.43% and +0.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Medical technology company Enovis Corporation (NYSE:ENOV) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 3.2% year on year to $582.8 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.34 billion at the midpoint. Its non-GAAP profit of $0.90 per share was 6.3% above analysts’ consensus estimates.

Dallas, TX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 3, 2026....

Enovis (ENOV) Reports Q2: Everything You Need To Know Ahead Of Earnings

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

Recent commentary on Enovis (ENOV) has focused on declining annual sales and weaker returns on capital, raising questions about how effectively the company is using its investments to create long term value for shareholders. See our latest analysis for Enovis. Despite concerns about Enovis's fundamentals, recent trading has been strong, with a 1 month share price return of 29.99% and a 90 day share price return of 31.26%, while the 3 year total shareholder return has declined 53.68%. Recent...

In recent months, Enovis has reported annual sales declines and weakening returns on capital, pointing to pressure on its existing growth and profitability engines. This shift suggests that earlier profit drivers may be fading and current growth initiatives are not yet offsetting operational challenges, raising questions about the efficiency of its capital deployment. We’ll now explore how concerns over diminishing returns on capital could reshape Enovis’s previously optimistic investment...

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.